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Congestive heart failure (CHF) is characterized by impaired left ventricular function,
increased peripheral and pulmonary vascular resistance and reduced exercise tolerance and
dyspnea. Thus, mediators involved in the control of myocardial function and vascular tone
may be involved in its pathophysiology. The family of endothelins (ET) consists of four
closely related peptides, ET-1, ET-2, ET-3 and ET-4, which cause vasoconstriction, cell
proliferation and myocardial effects through activation of ETA receptors. In contrast,
endothelial ETB receptors mediate vasodilation via release of nitric oxide and prostacyclin. In
addition, ETB receptors in the lung are a major pathway for the clearance of ET-1 from
plasma. Thus, infusion of an ETA-receptor antagonist into the brachial artery in healthy
humans leads to vasodilation, whereas infusion of an ETB-receptor antagonist causes
vasoconstriction. Endothelin-1 plasma levels are elevated in CHF and correlate both with
hemodynamic severity and symptoms. Plasma levels of ET-1 and its precursor, big ET-1, are
strong independent predictors of death after myocardial infarction as well as in CHF.
Endothelin-1 contributes to increased systemic and pulmonary vascular resistance, vascular
dysfunction, myocardial ischemia and renal impairment in CHF. Selective ETA, as well as
combined ETA/B-receptor antagonists, have been studied in patients with CHF, and their use
has shown impressive hemodynamic improvement (i.e., reduced peripheral vascular and
pulmonary resistance as well as increased cardiac output). These results indicate that
ET-receptor antagonists, indeed, have a potential to improve hemodynamics, symptoms and,
potentially, prognosis in patients with CHF, which still carries a high mortality. (J Am Coll
Cardiol 2001;37:1493–505) © 2001 by the American College of Cardiology
Over a decade ago, a novel vasoconstrictor peptide synthe-
sized by vascular endothelial cells was identified (1,2). Since
then, knowledge about the role of endothelin (ET) in
disease has rapidly accumulated, and the fruits of this
research led to the development of specific antagonists of
ET receptors. This review will focus on the role of ET and
ET-receptor antagonists in the pathophysiology and phar-
macotherapy of congestive heart failure (CHF).
Congestive heart failure is a disease process characterized
by impaired left ventricular function, increased peripheral
and pulmonary vascular resistance and sodium and water
retention. Since the prevalence of CHF increases, it will be
a major cause of morbidity and mortality in the future (3).
Despite progress in pharmacotherapy, CHF still carries a
very high mortality (4,5).
ETs. The family of ETs consists of four closely related
peptides—ET-1, ET-2, ET-3 and ET-4–which are con-
verted by ET-converting enzymes from “big ETs,” origi-
nating from large preproendothelin peptides (6–9). The ET
peptides are synthesized by endothelial and smooth muscle
cells, as well as neural, renal, pulmonal and inflammatory
cells (10,11). Endothelins are structurally closely related to
neurotoxins produced by scorpions and snakes (12–14). The
major isoform in the cardiovascular system is ET-1. Factors
modulating the expression of ET-1 are shear-stress, pulsa-
tile stretch, epinephrine, angiotensin II, cortisol, thrombin,
inflammatory cytokines (tumor necrosis factor a,
interleukin-1 and -2), transforming growth factor b and
hypoxia (Fig. 1) (15–28). In the myocardium, prolonged
exercise induces ET-1 expression (29). Endothelin-1 is
metabolized by a neutral endopeptidase, which also cleaves
natriuretic peptides (30,31).
Endothelin-1 exerts its major vascular effects—
vasoconstriction and cell proliferation—through activation
of specific ETA and ETB receptors on vascular smooth
muscle cells (Fig. 1) (32–40), which leads to increased
intracellular calcium concentrations (33,36,41– 46).
Endothelin-1, most of which is secreted abluminally
(47,48), contributes to the maintenance of basal vascular
tone (Fig. 2A) (49). Additionally, ET-1 influences myocar-
dial contractility, the central and autonomic nervous system
and the baroreflex (43,44,50–61). In the kidney, sodium
excretion is modulated (62). Endothelial ETB receptors
cause vasodilation via release of nitric oxide (NO) and
prostacyclin (Fig. 1 and 2) (63). Additionally, ETB receptors
in the lung are a major pathway for the clearance of ET-1
from plasma (64–67). EndothelinB receptors also contrib-
ute to the autocrine regulation of ET-1 synthesis (68–71).
These features explain why ET-1—which is essential for
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normal embryonic development (72–79)—plays the role of a
villain in CHF, which is characterized by increased periph-
eral resistance and volume retention. Indeed, ET-1 contrib-
utes to vasoconstriction, decreased ventricular function and
volume retention in CHF. Endothelin-1 plasma levels are
elevated in patients with CHF, correlate with symptoms
and with the hemodynamic severity and are associated with
adverse prognosis (80–84).
Pathogenetic role of ET. HYPERTENSION. Arterial hyper-
tension is an important precursor of CHF, even in the
absence of myocardial infarction (MI) (85,86). Hyperten-
sion is associated with endothelial dysfunction (87,88), a
term describing the imbalance of endothelium-derived vaso-
dilating and -constricting substances (89,90). Endothelin-1
acts as the natural counterpart of NO (Fig. 1), which exerts
vasodilating, antithrombotic and antiproliferative effects and
inhibits leukocyte-adhesion to the vascular wall (15). Be-
sides its blood pressure raising effect in man (91,92), ET-1
induces vascular and myocardial hypertrophy (93–95),
which are independent risk factors for cardiovascular mor-
bidity and mortality (96–98).
In fact, ET-1 plays an important role in hypertension.
Patients with hypertension exhibit an exaggerated vasodila-
tor response to ET-receptor blockade (99). Plasma levels,
however, are not consistently elevated in essential hyperten-
sion (100–102). Therefore, vascular, rather than plasma,
ET-1 levels must be elevated, or the sensitivity to endoge-
nous ET-1 seems to be altered in patients with hyperten-
sion. Indeed, in experimental hypertension, vascular ET-1
content is much more increased than are plasma levels of the
peptide (28,94,103). Furthermore, there is evidence that
certain polymorphisms of the genes coding for ET-1 and
ET receptors could be associated with higher blood pressure
levels (104–107).
In experimental hypertension, treatment with a selective
ETA-receptor antagonist attenuates left ventricular hyper-
trophy (108), prevents vascular hypertrophy (103) and
ameliorates endothelial dysfunction (109,110). Therefore,
ET-receptor blockade opens new therapeutic options in
hypertension and its clinical sequelae. In essential hyperten-
sion, bosentan, a mixed ETA/B-receptor antagonist, de-
creases arterial blood pressure to a similar degree as an
angiotensin-converting enzyme (ACE) inhibitor (111).
This effect did not provoke any neurohormonal activation.
Further trials are needed to clarify if ET-receptor antago-
nists offer additional benefits over conventional antihyper-
tensive drugs.
Atherosclerosis. Coronary atherosclerosis, and, as a con-
sequence, myocardial ischemia and MI, is the chief etiology
of CHF (112). Endothelin-1 essentially contributes to
coronary artery disease (CAD) as ET-1 promotes direct
vasoconstriction and induces smooth muscle cell prolifera-
tion through activation of ETA receptors (1,35,113–115).
Furthermore, ET-1 stimulates neutrophil adhesion and
platelet aggregation (Fig. 1) (116,117) and functionally acts
as a natural antagonist of NO, a vasodilator with antipro-
liferative and antithrombotic properties (118–120). An
imbalance of NO and ET-1, thus, contributes to athero-
genesis (89).
Oxidatively modified low-density lipoprotein cholesterol
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
CAD 5 coronary artery disease
CHF 5 congestive heart failure
ET 5 endothelin
MHC 5 myosin heavy chain
MI 5 myocardial infarction
NO 5 nitric oxide
Figure 1. Endothelin-1 (ET-1) exerts vasoconstriction and proliferation via ETA receptors on smooth muscle cells. Endothelial ETB receptors mediate
vasodilation via release of nitric oxide (NO) and prostacyclin. EndothelinB receptors in the lung clear ET-1 from plasma. AI/II 5 angiotensin I/II;
AT 5 angiotensin receptor; cAMP 5 cyclic adenosine monophosphate; cGMP 5 cyclic guanosine monophosphate; COX 5 cyclo-oxygenase; ECE 5
endothelin-converting enzyme; IL 5 interleukin; L-Arg 5 L-arginine; NOS 5 nitric oxide synthase; oxLDL 5 oxidized low density lipoprotein; PGI2 5
prostacyclin; SR 5 scavenger receptor; T 5 thrombin receptor; TGF 5 transforming growth factor; Thr 5 thrombin.
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induces the production of ET-1 by human macrophages
and increases ET-1 release from endothelial cells (Fig. 1)
(16). Further risk factors for atherosclerosis, for example,
diabetes mellitus and smoking, also enhance endothelial
ET-1 secretion (121,122). Indeed, circulating and vascular
tissue levels of ET-1 are elevated in patients with athero-
sclerosis and correlate with the number of anatomic sites
involved (123–127). Moreover, tissue ET-1 levels correlate
with angina class in patients with CAD and increase as the
clinical presentation becomes unstable (128,129). Certain
polymorphisms of the prepro-ET-1 and ET-receptor genes
may represent a predisposition for vascular diseases (130–
134).
Experimentally, ET-receptor blockade prevents endothe-
lial dysfunction and structural vascular changes in athero-
sclerosis (103,135,136). In patients with CAD, ET-1 is an
important determinant of coronary tone (137). Future trials
will be required to delineate the role of ET antagonists in
the prevention of atherosclerosis.
ET in MI. Endothelin-1 plasma levels are elevated in
patients with acute MI and correlate with one-year prog-
nosis (Fig. 3) (125,138–140). Experimentally, treatment
with an ETA-receptor antagonist reduces infarct size and
improves survival (141–146).
ET in heart failure. Increased peripheral vascular resis-
tance is a key feature of CHF making ET-1 a pathophys-
iological suspect. Indeed, apart from activation of other
neurohormonal systems, ET-1 contributes to vasoconstric-
tion as well (Fig. 4) (147–149).
The production of ET-1 in the heart of rats with CHF is
markedly increased (150,151), and in the peripheral circu-
lation, particularly in the lung, ET-1 production is increased
(152–154). As a consequence, plasma levels of ET-1 are
elevated in experimental CHF (155), as is the density of
myocardial ET receptors (154,156).
In patients with CHF, circulating ET-1 is elevated and
correlates with hemodynamic severity (Fig. 5) and symp-
toms (80–83,157–160). Tissue ET-1 levels are also in-
creased in the failing human heart (161,162). Most impres-
sive, plasma levels of the ET-1 precursor, big ET-1, are
strong independent predictors of death (84,163–165).
Parallel to ET-1, ETA receptors are upregulated in the
failing human heart (166). In contrast, ETB receptors seem
to be downregulated (162). The vasoconstrictor response to
exogenous ET-1 is blunted in CHF as compared with
healthy subjects, both in the arterial and venous arms of the
circulation (167,168).
The mechanisms leading to increased ET-1 expression in
CHF are not completely understood. In CHF, the main
source of circulating ET-1 seems to be the pulmonary
vascular bed (169). Since there is a correlation between
ET-1 plasma levels and cardiac filling pressures and the
degree of pulmonary hypertension, respectively, vascular
distension may be a stimulus for increased ET-1 production
(157). Indeed, ET-1 production is modulated by barore-
flexes (170), and baroreceptor function, as well as the
normal increase in ET-1 plasma levels in response to
postural change, is disturbed in patients with CHF
(171,172). Additionally, decreased shear-stress caused by
low-cardiac output may also contribute to elevated ET-1
release in CHF (173,174). Downregulation of lung ETB
receptors, which are involved in clearance of ET-1 (Fig. 4),
may further contribute to elevated circulating ET-1 levels
(175,176). Other neurohormonal systems activated in CHF,
such as angiotensin II and catecholamines, may also stim-
ulate ET-1 production (177), as beta-adrenergic blocking
agents and certain ACE inhibitors lower circulating ET-1
levels (178,179). In addition, endothelial dysfunction with
an imbalance of endothelium-derived substances and de-
creased NO bioavailability in particular (119,180,181), par-
Figure 2. EndothelinA (ETA) receptors in the human forearm vasculature cause vasoconstriction, whereas ETB receptors mediate vasodilation via release
of nitric oxide (NO). (A) When BQ-123 (10 nmol/min), a selective ETA-receptor antagonist, is infused intra-arterially in healthy subjects, a progressive
increase in forearm blood flow is noted. In contrast, intra-arterial infusion of BQ-788 (1 nmol/min), a selective ETB-receptor antagonist, decreases forearm
blood flow. (B) Vasodilation induced by infusion of BQ-123 (100 nmol/min; intra-arterially) in healthy subjects is attenuated by inhibition of NO synthesis
with L-NMMA (200 mg/100 ml forearm volume) and concomitant sodium nitroprusside (12 to 30 ng/min, adjusted to restore basal blood flow) infusion
(“NO clamp”). Acetylsalicylic acid (600 mg orally) had no effect on BQ-123-induced vasodilation. (Modified from [63]).
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ticipates in the activation of the ET-1 pathway (182). As
mononuclear cells are capable of ET-1 production, chronic
immunologic activation, which occurs in CHF (183,184),
could also be implicated in ET-1 activation. Indeed, isolated
lymphocytes from patients with CHF, but not healthy
controls, show spontaneous ET-1 release (185).
Interestingly, ET-1 seems to exert differential effects on
myocardial contractility in the normal and the failing
human heart (50,51). In patients with reduced left ventric-
ular function, intracoronary infusion of the selective ETA-
receptor antagonist BQ-123 increases contractility, while, in
patients with normal ejection fraction, a decrease in con-
tractility occurs. However, ET-1 is not as important as the
beta-adrenoceptor pathway is for the regulation of myocar-
dial performance (186).
Renal function in CHF. Sodium and water retention
leading to edema is a clinical hallmark of CHF. Renal
function in patients with CHF is often impaired because of
renal hypoperfusion caused by low cardiac output and
neurohormonal activation.
Endothelin-1 has impact on the regulation of normal
renal function in addition to its cardiovascular effects (Fig.
4) (187–194). Systemic infusion of ET-1 in healthy volun-
teers leads to a decrease in renal plasma flow and glomerular
filtration rate. Urinary sodium excretion is reduced by a
decrease in both sodium and water reabsorption in the distal
tubules (62). Thus, renal function depends, in part, on
circulating ET-1 levels.
ET antagonists in CHF. Given the contribution of ET-1
to the hemodynamic derangement in patients with CHF,
specific pharmacotherapy aiming at prevention of the ac-
tions of the peptide is a logical approach. As established
therapeutic strategies in CHF such as ACE inhibition, and
beta-blockade in particular (195–198), proved blockade of
activated neurohormonal systems is a promising target.
Endothelin-receptor antagonism has already demonstrated
the amelioration of the clinical status of patients with CHF
and, thus, holds the potential to improve the outcome.
Mixed ETA/B-receptor antagonists. Several ET antago-
nists are under clinical investigation in cardiovascular dis-
eases (Table 1). Administration of the mixed ETA/B antag-
onist bosentan (Ro 47-0203) in rats with CHF after acute
MI significantly decreased arterial blood pressure and had in
effect additive to that of an ACE inhibitor (199).
Infusion of the mixed ETA/B antagonist bosentan im-
proves systemic and pulmonary hemodynamics in patients
with CHF, both acutely and chronically (137,200,201). A
clinical trial (Research on Endothelin Antagonists in
Chronic Heart failure [REACH]-1) investigating the long-
term effects of bosentan on clinical events in CHF showed
an improvement in symptoms (202). However, the trial had
to be stopped prematurely because of elevation of liver
transaminases. Bosentan, which was given in large oral
dosages, interacts with bile acid excretion. Lower dosages of
bosentan are currently being evaluated (ENABLE trial)
(Table 2).
Endothelin antagonists may also be of pharmacothera-
peutic value in renal failure, which often complicates the
pharmacological treatment of CHF. Experimentally, renal
vasoconstriction during reperfusion after clamping of the
renal artery can be significantly reduced by treatment with
an ET antagonist (203). Infusion of a selective ETA
antagonist one day after induction of acute renal failure
enhanced the tubular reabsorption of sodium, increased
glomerular filtration rate and improved survival (204). In
rats with experimental CHF, injection of bosentan, a mixed
ET antagonist, increased cortical and medullary blood flow
but reduced arterial pressure. In rats with compensated
CHF and in normal animals, bosentan did not affect blood
pressure and cortical perfusion (205).
Selective ETA-receptor antagonists. Theoretically, selec-
tive ETA antagonists may offer advantages over mixed
ETA/B antagonists. Endothelin-1 causes vasoconstriction
through activation of ETA and ETB receptors on smooth
muscle cells (32–37). In contrast, endothelial ETB receptors
evoke NO-mediated vasodilation and are involved in the
clearance of ET-1 (64–67,206,207) (Fig. 1). Reduced
pulmonary clearance of ET-1 may contribute to elevated
Figure 3. Circulating endothelin (ET) is a prognostic indicator of one-year
mortality after acute myocardial infarction (MI). (A) The relative risk of
death in patients with acute MI is determined by plasma ET-1. (B) The
proportion of patients surviving after acute MI is higher in patients with
low plasma ET. (Modified from [125]).
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Figure 4. Pathophysiological role of endothelin-1 (ET-1) in congestive heart failure. In the heart, ET-1 contributes to contractility. In addition to its
vasoconstrictive effects in the systemic and pulmonary circulation, ET-1 leads to hypertrophy of myocardial and smooth muscle cells. The pulmonary
circulation is an important source of ET-1 but is also involved in the clearance of ET-1. In the kidney, ET-1 regulates sodium and water excretion. ANP 5
atrial natriuretic peptide.
Figure 5. Hemodynamic severity of congestive heart failure correlates with circulating endothelin-1 (ET-1). There is an inverse relationship between stroke
volume and ET-1, whereas pulmonary vascular resistance is positively related to circulating ET-1. (Modified from [223]).
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circulating ET-1 levels in CHF (175). Thus, selective ETA
blockers interfere less with the clearance of ET-1 than
nonselective ETA/B antagonists do. Since endothelial ETB
receptors mediate the release of vasodilating NO, their
blockade may further deteriorate the balance of
endothelium-derived vasoactive substances (208,209).
Indeed, infusion of BQ-788, a selective ETB-receptor
antagonist, into the brachial artery caused vasoconstriction
in healthy volunteers, suggesting that activation of the
vascular ETB receptor by endogenous ET-1 overall favors
vasodilation (63) (Fig. 2A). Correspondingly, systemic in-
fusion of BQ-788 in healthy subjects increased peripheral
vascular resistance (Fig. 6) (206). Although BQ-788 had no
effect on mean arterial pressure, there was a reduction in
stroke volume index, giving further evidence for a theoret-
ical advantage of selective ETA antagonism in CHF. In the
human skin circulation, the ETA-receptor antagonist BQ-
123, but not the ETB blocker BQ-788, prevented ET-1-
induced vasoconstriction (210). However, the role of ETB
receptors may differ in healthy subjects and CHF. Whereas
ETB receptors mediate vasodilation in healthy subjects,
ETB receptors cause vasoconstriction, at least in the sys-
temic circulation, in patients with CHF (211).
Congestive heart failure is associated with the develop-
ment of myocardial hypertrophy as a response to chronic
volume overload. Endothelin-1 exerts growth-promoting
effects on cardiomyocytes (212), which are potentiated by
hypoxia and the renin angiotensin system (213,214). An
altered expression of myosin heavy chain (MHC), that is,
the switch from a- to b-MHC, is regarded as a molecular
marker for heart failure. BQ-123, a selective ETA blocker,
prevents the switch of MHC-isoform expression in exper-
imental heart failure (215).
In experimental heart failure, infusion of the selective
ETA antagonist, FR139317, improved cardiac performance
and renal perfusion, whereas administration of the ETB
blocker RES-701-1 decreased cardiac output and renal
plasma flow (207). RES-701-1 lowered circulating aldoste-
rone levels, while FR139317 led to a decrease in plasma
atrial natriuretic peptide (ANP) levels, which are elevated in
CHF due to atrial distension (216). Compared with the
mixed ETA/B antagonist TAK-044, the selective ETA
antagonist FR139317 improved hemodynamics to a com-
parable degree (217). Only TAK-044, however, lowered
plasma aldosterone levels, explainable by ETB-receptor-
mediated aldosterone release (Fig. 4). Darusentan, a selec-
tive ETA antagonist, attenuated the deterioration of cardiac
Table 1. Partial Listing of Endothelin Antagonists Under
Clinical Testing
Substance
Receptor
Selectivity Disease
BQ-123 A Transplantation, HF, MI, subarachnoid
hemorrhage, renal ischemia
BQ-788 B HF
BMS-193884 A HF
J-10432 A Hypertension
L-754142 A Renal ischemia
LU135252
(darusentan)
A HF, pulmonary hypertension, atherosclerosis,
progressive nephropathies
PD-142893 A/B Progressive nephropathy
PD-145065 A/B Subarachnoid hemorrhage
PD-156707 A HF
Ro 47-0203
(bosentan)
A/B Transplantation, HF, MI, atherosclerosis,
pulmonary hypertension, subarachnoid
hemorrhage, renal ischemia, progressive
nephropathies
Ro 61-1790 A Subarachnoid hemorrhage
SB-209670 A/B Radiocontrast nephropathy
TA-0115 A HF
TAK-044 A/B Atherosclerosis, subarachnoid hemorrhage,
renal transplant rejection
ZD 1611 A Obstructive lung disease, pulmonary
hypertension
HF 5 heart failure; MI 5 myocardial infarction.
Table 2. Ongoing Clinical Trials With ET Antagonists in CHF or Pulmonary Hypertension
Study Compound Patients Primary End Point
Results
Available
HEAT Darusentan HF Chronic hemodynamic efficacy Abstract (225)
ET-005 Darusentan HF LV mass and function, symptoms —
ENABLE Bosentan HF Combined morbidity and mortality —
Bosentan Pulmonary hypertension Change in six-minute walk test Abstract (226)
Tezosentan Acute HF Hemodynamics Abstract (227, 228)
BMS-193884 HF Hemodynamics Abstract (224)
ENABLE denotes Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure; CHF 5 congestive heart
failure; ET 5 endothelin; HEAT 5 Heart Failure ET(A) Receptor Blockade trial; HF 5 heart failure; LV 5 left ventricular.
Figure 6. Systemic infusion of BQ-788 (300 nmol/min), a selective
ETB-receptor antagonist, in healthy subjects increases systemic vascular
resistance (SVR) and decreases heart rate (HR), cardiac index (CI) and
stroke volume index (SVI). There was no significant change in systemic
arterial blood pressure (MAP). (Modified from [206]).
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performance and hemodynamics in dogs with pacing-
induced CHF (218). In a rat model of heart failure,
ventricular function was preserved by selective ETA antag-
onism (219). A-127722 and PD 156707, two further
selective ETA blockers, also improved hemodynamics when
given chronically (219,220). There was an accompanying
suppression of plasma ANP levels with improved sodium
excretion. Most encouraging, long-term survival was im-
proved by selective ETA antagonism in a rat model of CHF
(146).
It has been speculated that selective ETA antagonists may
be less potent than mixed ETA/B blockers. However, newer
selective ETA antagonists are able to achieve similar hemo-
dynamic effects as mixed ETA/B blockers when given to
patients with CHF (221). Systemic and pulmonary hemo-
dynamics markedly improved after intravenous infusion of
BQ-123, although patients were receiving long-term ACE-
inhibitor therapy, which was continued on the study day.
Indeed, the vasodilator action of ETA-receptor antagonism
is preserved in patients with CHF treated with an ACE
inhibitor (222).
Darusentan is a selective ETA-receptor antagonist for
oral administration that has been studied both acutely as
well as chronically, that is, over a period of three weeks, in
patients with moderate CHF (223). Impressive hemody-
namic improvements were achieved (Fig. 7). While there
was a marked decrease in systemic and pulmonary vascular
resistance, cardiac output greatly improved without causing
neurohormonal stimulation. Circulating ET-1 increased—
most likely due to displacement of ET-1 from the ETA
receptor—after administration of the ETA blocker, but the
elevation was clearly less pronounced than with the use of
the mixed ETA/B-receptor antagonist bosentan (200,201).
With a further selective ETA antagonist BMS-193884
comparable hemodynamic improvements were achieved as-
sociated with a trend for improvement of symptoms (224).
As is the case for darusentan, the compound was well-
tolerated and did not provoke any elevation of liver
transaminases. Table 2 summarizes further ongoing clinical
trials (225–227).
Taken together, there is evidence for the preferential use
of selective ETA blockers for CHF. However, randomized
clinical trials are needed to compare the effects of ETA with
mixed ETA/B-receptor antagonists on clinical outcome of
patients with CHF.
Conclusions. Circulating ET-1 levels, which are elevated
in CHF, correlate with the hemodynamic severity, with
symptoms and with prognosis of the disease. Recent trials
with ET blockers, which ameliorate symptoms and hemo-
dynamics in CHF, indicate that ET-receptor antagonism,
Figure 7. Hemodynamic effects of the selective endothelinA (ETA)-receptor antagonist darusentan after oral administration in moderate congestive heart
failure. Darusentan caused a dose-dependent decrease in systemic and pulmonary vascular resistance, whereas cardiac index increased. Plasma
catecholamines and heart rate did not change. (Modified from [223]).
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indeed, holds the potential to improve the prognosis of
CHF, which still carries high morbidity and mortality.
Large clinical trials—in part under way—are now required
to prove this hypothesis.
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